Does allele-specific silencing with miRYR2-U10 prevent life-threatening arrhythmias in CPVT mice?
Reduction of mutant RyR2 via allele-specific silencing represents a potential novel therapeutic approach for catecholaminergic polymorphic ventricular tachycardia (CPVT).
The study demonstrates that allele-specific silencing with miRYR2-U10 prevents life-threatening arrhythmias in CPVT mice, suggesting that the reduction of mutant RyR2 may be a novel therapeutic approach for CPVT.
Bongianino et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: